Hi @Sponge,
I had an opportunity some time ago to examine this potential operations cost issue for MSB.
On one analysis, there are 2 broad ways that 'sweet, sweet money' might be a reason for the FDA to "say it appeared sufficient for resubmission if it appeared that it was not approvable" i.e. properly & improperly.
Re the first, MSB holders should be aware of the cost savings for MSB built into the current Prescription Drug User Fee Amendments, viz:
Link here.
IMO, Mesoblast Ltd would not have to shell out to the FDA any "sweet, sweet money" to have any resubmission of the RYONCIL BLA accepted for filing and/ or reviewed fully by the FDA in a new review cycle i.e either because RYONCIL's paediatric indication is covered by an ODD (as it is & has been for some time), or alternatively because MSB has already paid the fee on a BLA that was accepted for filing but not approved by the FDA at the time.
So, then re the second, please do tell all HC:MSB readers in great detail exactly what improper way you might be suggesting that the FDA received "sweet, sweet money" in connection with the recently ASX-announced RYONCIL resubmission, & from whom exactly they received it.
Or you could just withdraw the suggestion. As the animal act it was.
GLTA(LT)H
- Forums
- ASX - By Stock
- Ann: Mesoblast Resubmits BLA with FDA for Ryoncil Approval
Hi @Sponge, I had an opportunity some time ago to examine this...
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.46 |
Change
0.005(0.34%) |
Mkt cap ! $1.649B |
Open | High | Low | Value | Volume |
$1.46 | $1.49 | $1.44 | $1.970M | 1.354M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 3177 | $1.46 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.46 | 18057 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 4577 | 1.455 |
7 | 23372 | 1.450 |
8 | 66766 | 1.445 |
11 | 114434 | 1.440 |
6 | 33077 | 1.435 |
Price($) | Vol. | No. |
---|---|---|
1.460 | 21285 | 6 |
1.465 | 25515 | 9 |
1.470 | 73689 | 8 |
1.475 | 72680 | 8 |
1.480 | 120854 | 9 |
Last trade - 12.45pm 21/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online